Cathepsin L-Cleavable ADC Linker for Stable Tumor Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing conjugate drugs lack stability and efficacy in targeting tumor cells, leading to inefficient release of cytotoxic molecules and potential off-target toxicity.
Innovation Solution
A linker (-GGFL-) that is specifically cleaved by cathepsin L in tumor environments, ensuring high stability outside tumors and rapid release of cytotoxic substances within, while maintaining stability in non-tumor environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional linkers are used in conjugate drugs, then the drugs can be administered systemically, but the drugs lack stability and show off-target toxicity
Solution Approach 1:
The patent applies parameter changes by designing a linker with specific amino acid sequence (-GGFL-) that changes its stability parameter based on the enzymatic environment. The linker is stable in normal physiological conditions but becomes unstable when exposed to cathepsin L in tumor microenvironment, enabling selective drug release only at the target site and reducing off-target toxicity
Solution Approach 2:
The patent uses cathepsin L as an intermediary enzyme that mediates the cleavage of the linker. The linker sequence -GGFL- is specifically designed to be recognized and cleaved by cathepsin L, which is overexpressed in tumor cells. This intermediary mechanism ensures that the cytotoxic drug is released only when the conjugate is internalized by tumor cells, providing selective targeting and reducing systemic toxicity
2Productivity
If the linker is designed to be cleaved by cathepsin L, then rapid release of cytotoxic substances occurs in tumors, but stability in non-tumor environments must be maintained
Solution Approach 1:
The patent applies local quality by designing the linker with different stability characteristics for different locations. The -GGFL- sequence maintains stable composition in non-tumor environments (blood circulation, normal tissues) but is designed to be rapidly cleaved in the specific local environment of tumor cells where cathepsin L is present, achieving location-dependent drug release
Solution Approach 2:
The patent implements dynamics by creating a linker whose stability is not fixed but changes dynamically based on the enzymatic environment. The linker transitions from a stable state in circulation to an unstable state upon encountering cathepsin L, enabling the system to adapt its drug release properties according to the biological environment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances tumor-targeted drug delivery with high specificity and reduced off-target toxicity, achieving effective cytotoxicity in tumors with minimal side effects.
Implementation Method 1
A linker (-GGFL-) that is specifically cleaved by cathepsin L in tumor environments
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are a linker and a drug conjugate using same, and an antibody-drug conjugate and a use thereof. Specifically, provided is a conjugate as shown in formula (II) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein L is a linker (-GGFL-) as shown in formula (I). The conjugate comprising the linker as shown in formula (I) has high stability at a non-target site and can be quickly activated at a target site R1-L-R2 Formula (II)